Thus, for example, IL-2 that is now combined with anti-GD2 mAb in NB immunotherapy clinical trials in order to potentiate NK cell-mediated ADCC, is a potent inducer of IFN-γ, whose availability in vivo can provoke HLA class I upregulation on NB cells and therefore increase the immunogenicity of the latter cells. Here, IFNG is linked to neuroblastoma.